Core Viewpoint - Zhejiang Shimai Pharmaceutical Co., Ltd. has submitted its prospectus for an IPO on the Hong Kong Stock Exchange, with Huatai International as the sole sponsor, amid a backdrop of significant interest in TCE therapies and multiple rounds of financing from investors like Betta Pharmaceuticals [1][2]. Group 1: Company Overview - Founded in 2017, Shimai Pharmaceutical focuses on the development of TCE (T-cell engager) drugs, with no products commercialized yet and four clinical-stage candidates in its pipeline [2]. - The company reported revenues of 14.65 million yuan, 6.62 million yuan, and 2.28 million yuan for 2023, 2024, and the first half of 2025, respectively, with corresponding losses of 74.94 million yuan, 59.89 million yuan, and 25.42 million yuan, totaling over 160 million yuan in cumulative losses [2]. - The company has received three rounds of financing, with a post-Series C valuation of 2.23 billion yuan, and its major shareholders include the controlling shareholder Xiaozuoxiang and Betta Pharmaceuticals [2]. Group 2: Financial Management - The current CFO, Liu Yang, joined the company shortly before the IPO process, bringing over 12 years of experience in the international healthcare industry and capital markets [4]. - The company has seen frequent changes in its financial leadership, with four different CFOs from 2021 to 2025, indicating potential instability in financial management [5]. - Despite a peak net asset value of 236 million yuan, the company has shown a preference for structured deposits, with financial assets of 216 million yuan, 164 million yuan, and 67 million yuan for the years 2023, 2024, and the first half of 2025, respectively [6]. Group 3: Research and Development - The company has reduced R&D expenses significantly, with expenditures of 76.11 million yuan, 53.38 million yuan, and 22.39 million yuan for 2023, 2024, and the first half of 2025, respectively, alongside a decrease in administrative expenses [7]. - The R&D investment for core products DNV3 and SMET12 has also seen substantial cuts, raising concerns about the company's commitment to its pipeline [7]. - The safety profile of the core products remains a concern, with high rates of adverse events reported in clinical trials, including 81.8% for DNV3 and 93.8% for SMET12 [8].

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Views - The report emphasizes three core investment directions: 1) Breakthroughs in cutting-edge technologies (e.g., First-in-class drugs in oncology, weight loss, autoimmune fields, and innovative devices like brain-machine interfaces); 2) Clinical validation and commercialization potential (focus on the progress of domestic innovative drugs going abroad and the clinical development progress post-BD transactions); 3) Efficiency advantages in the industry chain (CXO leaders and high-value consumables' global layout) [8] Industry Review - The pharmaceutical and biotechnology industry index increased by 0.81%, ranking 21st among 31 primary industries, outperforming the CSI 300 index which decreased by 0.27% [5][16] - The sub-industries of pharmaceutical circulation and in vitro diagnostics saw significant gains of 7.61% and 5.32% respectively, while medical research outsourcing and medical devices experienced declines of 3.49% and 1.76% [5][16] - As of November 14, 2025, the industry PE (TTM overall method, excluding negative values) was 30.89x, up from 30.67x in the previous period, indicating an upward valuation trend that remains below the average [21] - The top three PE ratios among the sub-industries were for vaccines (50.42x), hospitals (43.67x), and medical devices (37.84x), while pharmaceutical circulation had the lowest valuation at 15.46x [21] Important Industry News - The National Health Commission and others issued implementation opinions to promote and regulate the application of "AI + healthcare" [7] - The NMPA released a new version of the "Medical Device Production Quality Management Specifications" [7] - Novartis received NMPA approval for its first radioligand therapy drug "Pluvicto®" for dual indications [7] - Sanofi's innovative targeted nano-antibody "Cablivi®" was approved by NMPA for treating immune-mediated thrombotic thrombocytopenic purpura [7] - The U.S. government reached a drug price control agreement with Eli Lilly and Novo Nordisk, leading to significant price reductions for GLP-1 drugs [7]

Core Viewpoint - Zhejiang Shimai Pharmaceutical Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, focusing on the development of TCE drugs and aiming to raise funds for clinical development and operational needs [1][5]. Company Overview - Established in 2017, Shimai Pharmaceutical specializes in TCE drug development, with four clinical-stage candidates: DNV3, SMET12, CMD011, and CMDE005 [1]. - The company has a current valuation of 2.23 billion RMB following its latest Series C financing, attracting investments from notable pharmaceutical companies [1]. Financial Performance - For the reporting period from 2023 to the first half of 2025, Shimai Pharmaceutical reported other income and gains of 14.65 million RMB, 6.62 million RMB, and 2.28 million RMB, while total losses reached 74.94 million RMB, 59.90 million RMB, and 25.42 million RMB, accumulating over 160 million RMB in total losses [2][3]. - The company has not yet commercialized any products, leading to significant ongoing losses, with revenue primarily from government subsidies and investment income [2][4]. Research and Development - R&D expenses for the reporting period were 76.11 million RMB, 53.38 million RMB, and 22.39 million RMB, with a notable decrease in R&D spending raising concerns about the progress of core product development [4]. - The R&D expenditure for core product SMET12 decreased by 73.7% in the first half of 2025 compared to the same period in 2024, indicating potential challenges in sustaining development efforts [4]. Market Potential - The global TCE market is projected to reach approximately 3 billion USD by 2024, with a compound annual growth rate of 40% expected to grow to 121.1 billion USD by 2035. The Chinese TCE market is anticipated to reach 700 million RMB by 2024, with a growth rate of 63.8% projected to reach 159.6 billion RMB by 2035 [5].

Core Viewpoint - The surge in IPO applications from pharmaceutical companies in Hong Kong has created a competitive environment, leading to challenges in securing cornerstone investors and navigating the market dynamics [1][5]. Group 1: IPO Market Dynamics - The Hong Kong IPO market for healthcare has seen a significant recovery, with 23 companies successfully listed this year compared to only 8 last year [1]. - Over 40 healthcare companies have applied for IPOs this year, with 8 applications in just the first half of November [1]. - The competition among companies to attract suitable investors has intensified due to the increasing number of IPO applications [1][5]. Group 2: Specific Company Developments - Bai Li Tianheng's IPO was delayed due to market conditions, with reports suggesting that investor demand did not meet expectations [2][3]. - The company aimed to attract long-term value-focused investors rather than those interested in short-term gains [4]. - The IPO structure includes cornerstone placements, book-building placements, and public offerings, with cornerstone investors playing a crucial role in stabilizing the market perception of the IPO [4]. Group 3: Investor Behavior and Market Trends - Investors are currently more focused on new IPOs due to the significant gains seen in the secondary market this year, leading to a preference for new offerings over existing stocks [5]. - The participation of cornerstone investors has increased, with many successful IPOs this year having multiple cornerstone investors involved [7]. - Despite a recent cooling in the secondary market, the enthusiasm for IPO applications remains high, with expectations for several companies to list in the first quarter of next year [8][9]. Group 4: Future Outlook - The healthcare sector is still attracting attention from both international and domestic investors, with a focus on high-quality investment targets [10]. - The pricing strategy for upcoming IPOs will be critical, as sufficient discounting is necessary to garner investor interest [10].

Core Viewpoint - The article discusses the surge in IPO applications from pharmaceutical companies in Hong Kong, highlighting the competitive landscape and the challenges faced by these companies in securing investors amid a crowded market [3][5][10]. Group 1: IPO Market Dynamics - As of November 14, 2023, 23 healthcare companies have successfully listed on the Hong Kong stock market this year, compared to only 8 in the same period last year [3]. - Over 40 healthcare companies have applied for IPOs in Hong Kong this year, with 8 applications submitted in just the first half of November [3]. - The increase in IPO applications has led to heightened competition among companies to attract suitable investors, resulting in a more complex negotiation landscape between companies and institutional investors [3][5]. Group 2: Case Study of Baillie Gifford - Baillie Gifford's planned global offering was delayed due to market conditions, with reports suggesting that investor demand did not meet expectations [4][5]. - The company aimed to attract long-term value investors rather than those focused on short-term price fluctuations, indicating a strategic approach to its IPO [5][6]. - The IPO process involves cornerstone placements, book-building, and public offerings, with cornerstone investors playing a crucial role in validating the company's value [6]. Group 3: Market Sentiment and Trends - The pharmaceutical sector has seen significant stock price increases this year, leading investors to focus on new IPOs rather than existing stocks [7]. - The introduction of new IPO pricing mechanisms by the Hong Kong Stock Exchange has increased the participation of cornerstone investors in pharmaceutical IPOs [9]. - Despite a recent cooling in the secondary market, the enthusiasm for IPO applications remains strong, with expectations of multiple companies going public in the first quarter of the following year [10][11]. Group 4: Investment Focus Areas - Certain sectors within the pharmaceutical industry, such as siRNA and ADC drugs, are attracting more attention from investors, indicating a trend towards specialized investment opportunities [11]. - The competition among major pharmaceutical companies for acquisitions, particularly in the GLP-1 drug space, has heightened interest in related IPOs [11]. - The article notes that while many IPOs are being pursued, the quality of the offerings and their pricing will be critical in attracting investor interest [13].

Core Viewpoint - The surge in IPO applications from pharmaceutical companies in Hong Kong has created a competitive environment, leading to challenges in securing cornerstone investors and achieving favorable pricing for new listings [1][2][3]. Group 1: IPO Market Dynamics - The Hong Kong IPO market for healthcare has seen a significant recovery, with 23 companies successfully listed this year compared to only 8 last year [1]. - Over 40 healthcare companies have applied for IPOs this year, with 8 applications submitted in just the first half of November [1]. - The competition among companies to attract suitable investors has intensified due to the increasing number of IPO applications [1][4]. Group 2: Case Study of Baillie Gifford - Baillie Gifford's IPO plans were delayed due to unfavorable market conditions and insufficient demand from cornerstone investors [2][3]. - The company aims to attract long-term investors who value growth potential rather than short-term price fluctuations [3]. - The IPO structure includes cornerstone placements, book-building placements, and public offerings, with cornerstone investors playing a crucial role in establishing market credibility [3]. Group 3: Investor Sentiment and Market Trends - The performance of the pharmaceutical sector has been strong, with many stocks experiencing significant gains, leading investors to focus on new IPOs rather than existing stocks [4][5]. - Despite a recent cooling in the secondary market, the enthusiasm for IPOs remains high, with many companies eager to secure reputable cornerstone investors [5][8]. - The market is witnessing a differentiation in investor interest, with certain sectors like siRNA and ADC drugs attracting more attention [7][8]. Group 4: Future Outlook - Several companies are expected to launch IPOs in the first quarter of next year, as they aim to capitalize on favorable market conditions [7]. - The IPO pricing strategy is critical, as investors are looking for sufficient discount space to engage with new offerings [8].

Core Insights - On November 14, 2023, Benda Pharmaceutical conducted a block trade of 69,000 shares, amounting to 3.007 million yuan, which represented 0.98% of the total trading volume for the day [1][2] - The transaction price was 43.58 yuan per share, reflecting a discount of 19.77% compared to the market closing price of 54.32 yuan [1] Summary by Category Trading Activity - The block trade involved 69,000 shares of Benda Pharmaceutical [1][2] - The total transaction value was 3.007 million yuan [1][2] Price Analysis - The executed price of 43.58 yuan per share was significantly lower than the market closing price, indicating a discount of 19.77% [1] Brokerage Information - The buyer was Guangfa Securities Co., Ltd., and the seller was Founder Securities Co., Ltd. [2]

Core Viewpoint - Hanx Biopharmaceuticals (Wuhan) Co., Ltd. plans to issue up to 21,069,700 overseas listed ordinary shares and convert 117,897,830 domestic unlisted shares into overseas listed shares for trading on the Hong Kong Stock Exchange [1] Company Overview - Hanx Biopharmaceuticals is an innovative biotech company specializing in structural biology, translational medicine, and clinical development, with a focus on building an innovative pipeline since 2016 [1] - The company has developed a core product and nine other pipeline candidates, including three clinical-stage candidates targeting oncology (HX009, HX301, HX044) and seven preclinical candidates, which include antibody-drug conjugates, bispecific antibodies, and monoclonal antibodies targeting autoimmune and oncology markets [1] Shareholder Information - A total of 15 shareholders will convert their shares, with the largest shareholding being 55,300,000 shares from Cai Zhang Biotechnology (Hangzhou) Co., Ltd. [2] - Other significant shareholders include Hanx Biopharmaceuticals (HK) Limited with 17,793,640 shares and Beijing Longpan Biopharmaceutical Venture Capital Center (Limited Partnership) with 12,860,470 shares [2] - The total number of shares being converted amounts to 117,897,830 shares [2]

五、自本备案通知书出具之日起12个月内未完成境外发行上市及股份转换，拟继续推进的，应当更新备 案材料。 备案通知书同时明确，其仅对企业境外发行上市及"全流通"备案信息予以确认，不表明中国证监会对该 企业证券的投资价值或者投资者的收益作出实质性判断或者保证，也不表明对企业备案材料的真实性、 准确性、完整性作出保证或者认定。 2025年11月12日，中国证监会国际合作司发布关于翰思艾泰生物医药科技（武汉）股份有限公司（以下 简称"翰思艾泰"）境外发行上市及境内未上市股份"全流通"的备案通知书。 根据备案通知书内容，依据《中华人民共和国证券法》《境内企业境外发行证券和上市管理试行办法》 《H股公司境内未上市股份申请"全流通"业务指引》等规定，证监会对翰思艾泰备案事项作出如下通 知： 一、翰思艾泰拟发行不超过21,069,700股境外上市普通股并在香港联合交易所上市。 二、该公司15名股东拟将所持合计117,897,830股境内未上市股份转为境外上市股份，并在香港联合交易 所上市流通，具体股东名称及转换数量详见附件。 三、自本备案通知书出具之日起至本次境外发行上市结束前，翰思艾泰如发生重大事项，应根据境内企 业境外发 ...

Core Viewpoint - The China Securities Regulatory Commission has approved Hanx Biopharmaceuticals (Wuhan) Co., Ltd. to issue up to 21,069,700 overseas listed ordinary shares and convert 117,897,830 domestic unlisted shares into overseas listed shares for trading on the Hong Kong Stock Exchange [1] Company Overview - Hanx Biopharmaceuticals is an innovative biotech company specializing in structural biology, translational medicine, and clinical development, with a focus on building an innovative pipeline since 2016 [1] - The company has developed a core product and nine other pipeline candidates, including three clinical-stage candidates for oncology (HX009, HX301, and HX044) and seven preclinical candidates targeting autoimmune and oncology markets [1] Shareholder Information - A total of 15 shareholders will convert their shares, with the largest shareholding being from Cai Zhang Biotechnology (Hangzhou) Co., Ltd., holding 55,300,000 shares [2] - Other notable shareholders include Hanx Biopharmaceuticals (HK) Limited with 17,793,640 shares and Beijing Longpan Biopharmaceutical Venture Capital Center with 12,860,470 shares [2] - The total number of shares being converted amounts to 117,897,830 [2]